• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Experimental Hematology & Oncology

    Experimental Hematology & Oncology

    JournalISSN 2162-3619eISSN 2162-3619中科院 医学 2区

    年发文量

    研究主题

    论文(957)

    排序
    1NewRBP1-driven Retinol Metabolism in Tumor-Associated Lymphatic Endothelial Cells Orchestrates Triple-Negative Breast Cancer Progression and Lymphatic Metastasis
    Nieves Montenegro-Navarro, Estefanía Díaz del Cerro,Carmen Jordán-Pérez,Enrique de Álava,Melissa García-Caballero

    Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and is characterized by a high metastatic potential and limited treatment options. TNBC frequently metastasizes to lymphatic vessels and the presence of breast cancer cells in tumor-draining lymph nodes (LNs) is an important prognostic factor. Nevertheless, the molecular and metabolic reprogramming of TNBC-associated lymphatic vasculature remains poorly understood. A comprehensive single-cell RNA sequencing analysis of 44,000 endothelial cells from human breast tumor datasets was performed. RBP1, a retinol-binding protein, was identified as a metabolic gene highly and specifically upregulated in tumor-associated lymphatic endothelial cells (LECs). Then, RBP1 expression in human TNBC biopsies was assessed, and its association with LN status and overall patient survival was investigated in a cohort of 1,474 breast cancer patients. We further evaluated the in vivo relevance of RBP1 by CRISPR/Cas9-mediated Rbp1 knockout in a pre-clinical TNBC mouse model. In vitro functional studies were performed using co-culture systems and RBP1-silencing in LECs. Finally, RBP1 mechanism of action in the lymphatic vasculature was determined by bulk-RNA sequencing and validated by applying different cellular and molecular approaches. Single-cell profiling revealed that the metabolic gene RBP1 was upregulated in LECs within the human breast tumor microenvironment. Further analysis showed that lymphatic RBP1 expression was associated with LN metastases, and correlated with poor prognosis and reduced survival in TNBC patients. In the pre-clinical TNBC mouse model, CRISPR-Cas9-mediated Rbp1 knockout reduced lymphangiogenesis, tumor growth and metastatic burden, and increased necrosis. Moreover, functional assays demonstrated that direct co-culture of LECs with TNBC cells, or exposure to their secretome, induced lymphatic RBP1 upregulation and enhanced pro-lymphangiogenic activities, whereas RBP1 silencing compromised their biological, redox and metabolic properties. Mechanistically, bulk RNA sequencing of RBP1-silenced LECs combined with experimental validation revealed that RBP1, through its retinol-binding domain, modulates the VEGFR3 and NOTCH pathways, while also involving lipid mobilization. We define lymphatic RBP1 as a key “switch” that couples LEC metabolism to molecular programs, thereby driving tumor-associated lymphangiogenesis, breast tumor growth and lymphatic dissemination in TNBC. Our findings underscore the potential of RBP1 as both a novel prognostic biomarker and a tractable therapeutic target for blocking TNBC progression and lymphatic metastasis.

    2026
    引用
    AI阅读
    加入学术空间
    2NewCAR Immunotherapy for Cancer: from Ex Vivo Manufacturing to in Vivo Immune Cell Engineering
    Ziqiang Liu, Dezheng Kong, Pengwu Liang, Zhengze Li,Tingting Tan,Xin Dong,Ruizhen Li,Lifeng Li, Yi Zhang,Guozhu Xie

    Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has achieved durable remissions in patients with relapsed or refractory haematological malignancies. However, its broader clinical adoption remains constrained by patient-specific ex vivo manufacturing, substantial treatment-related toxicities and limited efficacy in solid tumours. In vivo CAR immunotherapy enables endogenous immune cells to be genetically reprogrammed directly within the body, bypassing leukapheresis, ex vivo expansion and individualized cell manufacturing. This Review focuses specifically on in vivo CAR immune cell engineering for cancer therapy, encompassing haematological malignancies and solid tumours; applications in non-malignant diseases, including autoimmune disorders, are outside its scope. We examine emerging technologies for generating CAR immune cells in vivo and discuss how viral vectors, non-viral nanocarriers and biomimetic delivery systems could improve the precision, scalability and controllability of cancer immunotherapy. We further highlight immune effectors beyond CAR T cells, including CAR macrophages and CAR natural killer cells, whose distinct cytotoxic, phagocytic and immunomodulatory functions may offer complementary approaches to treating solid tumours. We discuss strategies involving tumour-microenvironment remodelling, metabolic adaptation and precision genome engineering to improve immune-cell persistence, mitigate functional exhaustion, enhance tumour infiltration and limit antigen escape. Emerging clinical studies in haematological malignancies provide initial proof of concept that functional CAR cells can be generated in patients, although long-term safety, durability and reproducibility remain to be established. A central challenge is to generate these cells with sufficient cellular and spatial precision while maintaining control over their activity over time. We discuss how cell-subset-specific delivery, programmable CAR circuits, multicellular engineering, intelligent biomaterials and artificial intelligence could support the development of in vivo CAR immunotherapy as a scalable, controllable and potentially repeatable cancer treatment.

    2026
    引用
    AI阅读
    加入学术空间
    3NewSubtype-resolved Tumor-Intrinsic Programs in Immune-Cold Breast Cancer: Mechanistic Interactions, Evidence Gaps, and Translational Priorities
    Hung-Yu Lin, Shin-Mae Wang,Pei-Yi Chu

    Most breast cancers respond poorly to immune checkpoint blockade (ICB), and hormone receptor-positive (HR +) tumors, which constitute most diagnoses, are particularly refractory. This review synthesizes evidence on tumor-intrinsic determinants of the immune-cold phenotype in breast cancer under an operational framework designated ICE, comprising three functionally defined domains: Invisibility (failure of antigen generation, presentation, and innate sensing), Coercion (active exclusion and post-infiltration suppression of effector cells), and Exhaustion-by-Metabolism (metabolic attrition of infiltrating lymphocytes). ICE is not proposed as a newly discovered taxonomy of immune evasion; its added value lies in integrating breast-cancer subtype resolution, evidence provenance, systems-level interactions, negative clinical evidence, and mechanism–biomarker–intervention matching within a single operational framework. Four features define this framework. The domains are overlapping rather than sequential, and an explicit assignment rule places multifunctional regulators such as MYC, hypoxia-inducible factor 1α, and lactate in a primary domain while cataloguing secondary effects. Tumor–immune interaction is treated as bidirectional, positioning tumor-intrinsic programs as both causes and consequences of immune pressure. Major mechanistic and translational claims are assigned claim-specific evidence tiers. Resistance to immune-mediated killing, including death receptor loss, is classified as cross-dimensional cytoprotection rather than a recognition defect. Applying this discipline exposes an asymmetric evidence base: antigen presentation defects and metabolic suppression rest on substantial preclinical data with limited clinical validation, several widely cited mechanisms derive from non-breast models, and the translational record includes cross-cancer constraints—failure of IDO1 inhibition in a melanoma phase III trial and minimal STING-agonist monotherapy activity in early mixed-solid-tumor studies—together with breast-cancer-specific negative findings from IMpassion131 and the unfavorable benefit–risk profile of abemaciclib plus pembrolizumab. Cross-dimensional systems-level structures, including the hypoxia–adenylosuccinate lyase–fumarate–STING axis and the tumor–macrophage arginine–polyamine relay, are identified as the most instructive examples of domain interaction, and seven falsifiable predictions are advanced, each specifying a measurable biomarker and a decisive experiment.

    2026
    引用
    AI阅读
    加入学术空间
    4NewA Non-Imid Multi-Target Degrader Reactivates Fetal Hemoglobin
    Jun Liu,Ziyang Shen,Shin-Young Park, Yanhua Dong, Na Yu,Jing Zeng, Hannah Lee, Braden Pate,Sophia Adamia,Kim Vanuytsel,Junyan Zhang,Shang-Chuen Wu,

    Reactivation of fetal hemoglobin (HbF) is a validated therapeutic strategy for sickle cell disease (SCD) and β-thalassemia. Cereblon (CRBN)-dependent molecular-glue degraders of HbF repressors are advancing clinically, but all share an immunomodulatory imide drug (IMiD) backbone and its class liabilities. We show that SH6, a non-IMiD small-molecule degrader, consistently induces HbF in erythroid cell lines, primary healthy-donor, SCD, and β-thalassemia CD34⁺-derived erythroid cells, and humanized NBSGW mice, at nanomolar to low-micromolar concentrations. When all compounds were tested at a matched 0.25µM concentration, HbF induction by SH6 was comparable to that of decitabine and greater than that of hydroxyurea, pomalidomide or thalidomide. HbF induction is CRBN/proteasome-dependent and associated with simultaneous degradation of the γ-globin repressors ZBTB7A and BCL11A. These findings provide proof of concept for IMiD-independent pharmacologic HbF reactivation and support further study of SH6 as a mechanistically distinct tool compound.

    2026
    引用
    AI阅读
    加入学术空间
    5NewDistinct Asciminib Sensitivity Profiles Between BCR::ABL1 P190 and P210 Isoforms
    Elias Lagonik, Luke J. Quinlan,Elyse C. Page,Daniel P. McDougal,Laura N. Eadie,John B. Bruning,David T. Yeung,Timothy P. Hughes,Deborah L. White

    BCR::ABL1 is the oncogenic driver of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph + ) acute lymphoblastic leukemia (ALL), with BCR::ABL1 p210 and p190 being the predominant isoforms. Asciminib, an inhibitor that specifically targets the ABL myristate pocket (STAMP), has demonstrated efficacy in both pre-clinical and clinical studies against p210-driven CML, including cases where resistance mediated by ATP-pocket mutations has developed during prior tyrosine kinase inhibitor (TKI) therapy. The resistant mutation profile of asciminib is currently considered largely distinct from that of ATP-competitive TKIs. In our study, we demonstrate that several ATP-pocket mutations, including the V299L, F311I, T315I, and F317C/L, confer high levels of resistance to asciminib in the p190 isoform (> 1000-fold increase in LD50asciminib values compared to non-mutated BCR::ABL1 p190), but remain sensitive when occurring in the p210 isoform. The T315A was the only tested mutation in BCR::ABL1 p190 sensitive to asciminib. Furthermore, cells expressing BCR::ABL1 p190 mutations exhibited decreased kinase inhibition following STAMP treatment, indicative of an active kinase. Analogous results were obtained for MK-4208 (formerly known as TERN-701), a clinically active investigational STAMP compound. In the BCR::ABL1 p190 setting, this work reveals an overlapping resistance profile between STAMP compounds and TKIs, with important considerations for STAMP-based therapy. It challenges two key assumptions: that asciminib dose escalation can overcome resistant ATP-pocket mutations and that targeted therapy sensitivity profiles are equivalent between the p190 and p210 isoforms.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 957 篇论文

    高被引作者

    作者引用发文
    Kongming Wu127713
    Delong Liu124617
    Guoqing Wei9688
    Hui Hua7454
    Yangfu Jiang7454
    Hongying Zhang7454
    Kong Qingbin7213
    Ming Yi6558
    Shuang Qin6026
    Xu Hanxiao5633

    高产作者

    作者引用发文
    Delong Liu124617
    Yongping Song33713
    Kongming Wu127713
    Jianxiang Wang1109
    Zhijian Xiao1929
    Ming Yi6558
    Guoqing Wei9688
    Xin Du1608
    Qian Chu5628
    Zhongxing Jiang3278

    相关期刊

    Oncology research
    Cancer and Metastasis Reviews
    Cancer gene therapy
    Cancer biology & therapy
    Oncoimmunology
    Cancer drug resistance (Alhambra, Calif.)
    Cancer Immunology Research
    Biomarker Research
    Cellular Oncology
    Molecular Therapy - Oncolytics